{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:00:44Z","timestamp":1771304444227,"version":"3.50.1"},"reference-count":171,"publisher":"Elsevier","isbn-type":[{"value":"9780323899390","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"am","delay-in-days":665,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.ircmb.2021.05.005","type":"book-chapter","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T11:29:24Z","timestamp":1635420564000},"page":"179-226","source":"Crossref","is-referenced-by-count":6,"title":["Calreticulin mutations in myeloproliferative neoplasms"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2021.05.005_bb0010","doi-asserted-by":"crossref","first-page":"8844","DOI":"10.1128\/MCB.25.20.8844-8853.2005","article-title":"Retrotranslocation of the chaperone calreticulin from the endoplasmic reticulum lumen to the cytosol","volume":"25","author":"Afshar","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0015","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00277-017-2937-6","article-title":"Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory","volume":"96","author":"Agarwal","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0020","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alberto","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0025","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0030","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bjh.14762","article-title":"Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia","volume":"178","author":"Alvarez-Larr\u00e1n","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0035","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41375-018-0181-2","article-title":"Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation","volume":"33","author":"Araki","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0045","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0050","doi-asserted-by":"crossref","first-page":"9555","DOI":"10.1074\/jbc.RA118.002836","article-title":"Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I","volume":"293","author":"Arshad","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0055","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/leu.2016.47","article-title":"Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin","volume":"30","author":"Balligand","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0060","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41375-019-0538-1","article-title":"Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development","volume":"34","author":"Balligand","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0031-1291377","article-title":"Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment","volume":"37","author":"Ballmaier","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0070","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0075","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0080","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0085","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1038\/s41467-020-18691-3","article-title":"Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN","volume":"11","author":"Benlabiod","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0090","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature24627","article-title":"Structure of the human MHC-I peptide-loading complex","volume":"551","author":"Blees","year":"2017","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0095","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/bmt.2012.139","article-title":"Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia","volume":"48","author":"Buckley","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0100","doi-asserted-by":"crossref","first-page":"19039","DOI":"10.1016\/S0021-9258(18)41735-8","article-title":"Calreticulin in T-lymphocytes. Identification of calreticulin in T-lymphocytes and demonstration that activation of T cells correlates with increased levels of calreticulin mRNA and protein","volume":"267","author":"Burns","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/leu.2014.270","article-title":"Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution","volume":"29","author":"Cabagnols","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0110","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations","volume":"100","author":"Carla Al","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0115","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrc3171","article-title":"Programmed cell removal: a new obstacle in the road to developing cancer","volume":"12","author":"Chao","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00277-014-2232-8","article-title":"Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring","volume":"94","author":"Chi","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017886","article-title":"X-ray structure of the human Calreticulin globular domain reveals a peptide-binding area and suggests a multi-molecular mechanism","volume":"6","author":"Chouquet","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0135","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","article-title":"Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms","volume":"9","author":"Cimen Bozkus","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0140","doi-asserted-by":"crossref","first-page":"23132","DOI":"10.1074\/jbc.270.39.23132","article-title":"Inducible interaction of integrin \u03b12\u03b21 with calreticulin: dependence on the activation state of the integrin","volume":"270","author":"Coppolino","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/386843a0","article-title":"Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion","volume":"386","author":"Coppolino","year":"1997","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0150","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.exphem.2016.05.001","article-title":"Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis","volume":"44","author":"Daitoku","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0155","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.4161\/cc.10.10.15619","article-title":"Thrombopoietin and hematopoietic stem cells","volume":"10","author":"de Graaf","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0160","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/367480a0","article-title":"Inhibition of nuclear hormone receptor activity by calreticulin","volume":"367","author":"Dedhar","year":"1994","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0165","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1074\/jbc.M109.085407","article-title":"Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway","volume":"285","author":"Del Cid","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0170","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood.2019001103","article-title":"Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms","volume":"135","author":"Di Buduo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0175","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3324\/haematol.2013.096859","article-title":"The importance of calcium in the regulation of megakaryocyte function","volume":"99","author":"Di Christian Andrea","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0180","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/leu.2014.190","article-title":"Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling","volume":"28","author":"Eder-Azanza","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/clin.1994.1160","article-title":"Calreticulin is released from activated neutrophils and binds to C1q and mannan-binding protein","volume":"72","author":"Eggleton","year":"1994","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.24338","article-title":"Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia","volume":"91","author":"Elala","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0195","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0200","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2017-08-800896","article-title":"Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN","volume":"131","author":"Elf","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0205","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1038\/s41388-020-1368-3","article-title":"Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms","volume":"39","author":"El-Khoury","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0210","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24031","article-title":"ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia","volume":"90","author":"Elliott","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0215","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/ejh.12389","article-title":"Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history","volume":"94","author":"Gangat","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1074-7613(01)00260-6","article-title":"Assembly and antigen-presenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin","volume":"16","author":"Gao","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0245","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ajh.24245","article-title":"Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism","volume":"91","author":"Garbati","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0250","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1096\/fj.09-145482","article-title":"Calreticulin: non-endoplasmic reticulum functions in physiology and disease","volume":"24","author":"Gold","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0255","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0260","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0265","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/bjh.13644","article-title":"Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis","volume":"173","author":"Guglielmelli","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0270","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0275","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0280","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","article-title":"Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations","volume":"99","author":"Hajnalka","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0285","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-016-0275-0","article-title":"Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion","volume":"9","author":"Han","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0295","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molcel.2017.06.017","article-title":"The unfolded protein response and cell fate control","volume":"69","author":"Hetz","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0300","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.12772","article-title":"Thrombopoietin from beginning to end","volume":"165","author":"Hitchcock","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0305","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/leu.2016.233","article-title":"The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms","volume":"30","author":"Holmstr\u00f6m","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0310","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2017.214","article-title":"The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy","volume":"32","author":"Holmstr\u00f6m","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0315","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-018-0166-4","article-title":"High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals","volume":"9","author":"Holmstr\u00f6m","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0320","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1038\/emboj.2009.296","article-title":"Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide loading of MHC class I molecules","volume":"28","author":"Howe","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0325","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0330","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40259-016-0170-9","article-title":"Anagrelide and mutational status in essential thrombocythemia","volume":"30","author":"Iurlo","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0335","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0340","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0345","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1172\/JCI26674","article-title":"The molecular mechanisms that control thrombopoiesis","volume":"115","author":"Kaushansky","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0350","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia Vera, and myeloproliferative neoplasm, unclassifiable","volume":"143","author":"Kim","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0355","article-title":"Optimized detection of insertions\/deletions (INDELs) in whole-exome sequencing data","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0360","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0365","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0370","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/leu.2014.285","article-title":"MARIMO cells harbor a CALR mutation but are not dependent on JAK2\/STAT5 signaling","volume":"29","author":"Kollmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0375","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/leu.2016.280","article-title":"A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation","volume":"31","author":"Kollmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0380","series-title":"International Review of Cell and Molecular Biology","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/bs.ircmb.2019.07.005","article-title":"Chapter two\u2014antigen processing and presentation","volume":"Vol. 348","author":"Kotsias","year":"2019"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0385","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjh.14259","article-title":"Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis","volume":"179","author":"Kourie","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0390","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0395","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0400","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kr\u00f6ger","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0405","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2014-12-618074","article-title":"The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients","volume":"125","author":"Lau","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0410","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","article-title":"Population dynamics of normal human blood inferred from somatic mutations","volume":"561","author":"Lee-Six","year":"2018","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0415","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1074\/jbc.M115.696534","article-title":"His499 regulates dimerization and prevents oncogenic activation by asparagine mutations of the human thrombopoietin receptor","volume":"291","author":"Leroy","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0420","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0425","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","article-title":"Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0430","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1038\/bcj.2016.83","article-title":"Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish","volume":"6","author":"Lim","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0435","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.bbamcr.2010.03.001","article-title":"Suppression of MHC class I surface expression by calreticulin's P-domain in a calreticulin deficient cell line","volume":"1803","author":"Liu","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0440","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.molcel.2019.11.004","article-title":"Immunosuppression by mutated calreticulin released from malignant cells","volume":"77","author":"Liu","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0445","doi-asserted-by":"crossref","first-page":"526524","DOI":"10.1155\/2015\/526524","article-title":"Functional roles of calreticulin in cancer biology","volume":"2015","author":"Lu","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0450","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0455","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0460","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc1400499","article-title":"JAK inhibitor in CALR-mutant myelofibrosis","volume":"370","author":"Mario Cazzola","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0465","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0470","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjh.12969","article-title":"JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort","volume":"167","author":"McGaffin","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0475","first-page":"1411","article-title":"Calreticulin: a multifaceted protein","volume":"4","author":"Mendlovic","year":"2010","journal-title":"Nat. Educ."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0480","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1083\/jcb.144.5.857","article-title":"Calreticulin is essential for cardiac development","volume":"144","author":"Mesaeli","year":"1999","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0485","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BJ20081847","article-title":"Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum","volume":"417","author":"Michalak","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0490","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1016\/S0021-9258(20)89624-0","article-title":"Calreticulin, and not calsequestrin, is the major calcium binding protein of smooth muscle sarcoplasmic reticulum and liver endoplasmic reticulum","volume":"266","author":"Milner","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0495","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1538\/expanim.16-0043","article-title":"Generation of a transgenic mouse line for conditional expression of human IL-6","volume":"65","author":"Mori","year":"2016","journal-title":"Exp. Anim."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0500","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1083\/jcb.200102073","article-title":"Functional specialization of calreticulin domains","volume":"154","author":"Nakamura","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0505","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","article-title":"Somatic mutations and cell identity linked by genotyping of transcriptomes","volume":"571","author":"Nam","year":"2019","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0510","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0515","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","article-title":"Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms","volume":"130","author":"Nieborowska-Skorska","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0520","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/leu.2016.32","article-title":"Thrombopoietin receptor is required for the oncogenic function of CALR mutants","volume":"30","author":"Nivarthi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0525","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbapap.2008.05.005","article-title":"Small angle X-ray scattering study of calreticulin reveals conformational plasticity","volume":"1784","author":"N\u00f8rgaard Toft","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0530","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.194.6.781","article-title":"C1q and mannose binding lectin engagement of cell surface calreticulin and Cd91 initiates macropinocytosis and uptake of apoptotic cells","volume":"194","author":"Ogden","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0535","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0540","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0545","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/leu.2014.66","article-title":"Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Panagiota","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0550","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0555","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/leu.2014.306","article-title":"Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis","volume":"29","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0560","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0565","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0570","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2018-09-874578","article-title":"Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants","volume":"133","author":"Pecquet","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0575","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00277-016-2712-0","article-title":"Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis","volume":"95","author":"Pei","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0580","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0590","doi-asserted-by":"crossref","first-page":"e122703","DOI":"10.1172\/jci.insight.122703","article-title":"Targeting the CALR interactome in myeloproliferative neoplasms","volume":"3","author":"Pronier","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0595","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.stem.2007.10.008","article-title":"Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells","volume":"1","author":"Qian","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0600","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.it.2012.08.002","article-title":"Calreticulin in the immune system: ins and outs","volume":"34","author":"Raghavan","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0605","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0610","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1568813","article-title":"Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma","volume":"8","author":"Ren","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0615","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0620","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0625","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Ruben","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0630","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2014-01-550434","article-title":"CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0635","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0640","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0645","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ceb.2010.10.011","article-title":"Participation of lectin chaperones and thiol oxidoreductases in protein folding within the endoplasmic reticulum","volume":"23","author":"Rutkevich","year":"2011","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0650","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1074-7613(00)80487-2","article-title":"Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP","volume":"5","author":"Sadasivan","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0655","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1093\/emboj\/18.23.6718","article-title":"Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteins","volume":"18","author":"Saito","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0660","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jmcb\/mjw027","article-title":"Live-cell single-molecule imaging of the cytokine receptor MPL for analysis of dynamic dimerization","volume":"8","author":"Sakamoto","year":"2016","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0665","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s12094-017-1618-1","article-title":"Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis","volume":"19","author":"Saki","year":"2017","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0670","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/scd.2017.0137","article-title":"Calreticulin affects hematopoietic stem\/progenitor cell fate by impacting erythroid and megakaryocytic differentiation","volume":"27","author":"Salati","year":"2017","journal-title":"Stem Cells Dev."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0675","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1038\/s41598-019-46843-z","article-title":"Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants","volume":"9","author":"Salati","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0680","series-title":"International Review of Cell and Molecular Biology","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.ircmb.2019.08.004","article-title":"Chapter three\u2014the impact of endoplasmic reticulum stress responses in dendritic cell immunobiology","volume":"Vol. 349","author":"Salvagno","year":"2019"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0685","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019000519","article-title":"Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms","volume":"134","author":"Schischlik","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0690","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2017-02-768036","article-title":"Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in thrombopoietin","volume":"130","author":"Seo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0695","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12185-019-02803-x","article-title":"The role of driver mutations in myeloproliferative neoplasms: insights from mouse models","volume":"111","author":"Shide","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0700","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/leu.2016.308","article-title":"Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib","volume":"31","author":"Shide","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0705","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41408-019-0202-z","article-title":"Mice with CALR mutations homologous to human CALR mutations only exhibit mild thrombocytosis","volume":"9","author":"Shide","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0710","first-page":"106","article-title":"Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice","volume":"136","author":"Shide","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0715","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1038\/bcj.2014.7","article-title":"Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca2+: some mechanistic and therapeutic implications","volume":"4","author":"Shivarov","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0720","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1002\/j.1460-2075.1989.tb08530.x","article-title":"Multiple zones in the sequence of calreticulin (CRP55, calregulin, HACBP), a major calcium binding ER\/SR protein","volume":"8","author":"Smith","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0725","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/2159-8290.CD-16-0238","article-title":"Molecular mechanism of mutant CALR\u2013mediated transformation","volume":"6","author":"Stanley","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0730","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/asheducation-2018.1.264","article-title":"Clinical consequences of clonal hematopoiesis of indeterminate potential","volume":"2018","author":"Steensma","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0735","first-page":"202952","article-title":"Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease","volume":"2018","author":"Stengel","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0740","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0745","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/bjh.15266","article-title":"Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations","volume":"181","author":"Takei","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0750","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential thrombocythemia","volume":"381","author":"Tefferi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0755","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0760","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0765","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0770","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0775","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0780","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0785","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-018-0067-6","article-title":"Momelotinib therapy for myelofibrosis: a 7-year follow-up","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0790","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0795","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0800","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-018-0109-0","article-title":"Myelofibrosis treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0805","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: mayo-Careggi MPN alliance study of 1,095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0810","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-017-0041-8","article-title":"Essential thrombocythemia treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0815","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2016-02-696310","article-title":"Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency","volume":"127","author":"Theocharides","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0820","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41388-018-0538-z","article-title":"Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice","volume":"38","author":"Toppaldoddi","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0825","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bjh.13539","article-title":"Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation","volume":"172","author":"Torregrosa","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0830","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-018-0386-y","article-title":"Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies","volume":"6","author":"Tubb","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0835","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2014.100","article-title":"Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value","volume":"28","author":"Vannucchi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0840","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20141293","article-title":"JAK2 activation by growth hormone and other cytokines","volume":"466","author":"Waters","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0850","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1073\/pnas.1102524108","article-title":"Essential glycan-dependent interactions optimize MHC class I peptide loading","volume":"108","author":"Wearsch","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0855","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2017.157","article-title":"Impact of molecular residual disease post allografting in myelofibrosis patients","volume":"52","author":"Wolschke","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/bs.ircmb.2021.05.005_bb0860","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/ajh.24578","article-title":"Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms","volume":"91","author":"Xia","year":"2016","journal-title":"Am. J. Hematol."}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T11:10:33Z","timestamp":1753787433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780323899390"],"references-count":171,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.05.005","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}